We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......

Basic View | Expanded View
 Showing 21-40 of 81 Articles
Original Investigation 
Dong W. Chang, MD, MS; Martin F. Shapiro, MD, PhD
Includes: Supplemental Content

Importance  Maximizing the value of critical care services requires understanding the relationship between intensive care unit (ICU) utilization, clinical outcomes, and costs.

Objective  To examine whether hospitals had consistent patterns of ICU utilization across 4 common medical conditions and the association between higher use of the ...

Original Investigation 
Benjamin D. Sommers, MD, PhD; Robert J. Blendon, ScD; E. John Orav, PhD; Arnold M. Epstein, MD, MA
Includes: Supplemental Content

Importance  Under the Affordable Care Act (ACA), more than 30 states have expanded Medicaid, with some states choosing to expand private insurance instead (the “private option”). In addition, while coverage gains from the ACA’s Medicaid expansion are well documented, impacts on utilization and health are unclear.


Invited Commentary 
Traci C. Green, PhD, MSc; Michael Gilbert, MPH

The steep recent increase in overdose deaths and near-deaths nationwide involving fentanyl signals a new chapter in the epidemic of opioid use. Throughout the United States and Canada, seizures of pill presses, large quantities of active pharmaceutical ingredient in powder form, and counterfeit pills have been reported. Since ...

Invited Commentary 
Neil A. Halpern, MD, MCCM

The number of intensive care unit (ICU) beds in the United States has continued to increase over the last 3 decades, as have ICU utilization rates and costs,1,2 and this despite the lack of any federal, regional, or critical care society mandates to justify these ...

Invited Commentary 
Frank J. Thompson, PhD; Joel C. Cantor, ScD

We applaud the work of Sommers and colleagues1 in this issue to gauge the implications of different types of Medicaid expansions for pertinent measures of medical care access and quality as well as health. Their analysis clearly indicates that expanding Medicaid, whether through the Kentucky or Arkansas ...

Teachable Moment 
Shayan Nabavi Nouri, MD; Brian L. Block, MD

This Teachable Moment explores innovations that improve the ability to treat disease but increase the potential to cause harm, and thus the importance of careful consideration of who should be treated, what with, and for how long.

Research Letter 
Ann M. Arens, MD; Xander M. R. van Wijk, PhD; Kathy T. Vo, MD; Kara L. Lynch, PhD; Alan H. B. Wu, PhD; Craig G. Smollin, MD

This case series describes patients who experienced adverse effects associated with the ingestion of counterfeit alprazolam tablets.

Research Letter 
Marisa I. Peine, BA, BS; J. Roxanne Prichard, PhD; Ken M. Kunisaki, MD, MS

This study examines unauthorized online sales by private individuals of secondhand continuous positive airway pressure devices.


In the Original Investigation titled “Incidence of and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients in the Postoperative Period,”1 published online July 11, 2016, the middle initial was omitted from the second author’s name. The correct name is Beth D. Darnall, PhD. This article was ...

Peter C. Butler, MD

Two relatively new classes of therapeutics, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) agonists (Table 1 and Table 2), have been widely adopted in practice for diabetes management based on clinical trial evidence demonstrating effective glycosylated hemoglobin control, benefits for weight management, and low ...

Original Investigation 
Laurent Azoulay, PhD; Kristian B. Filion, PhD; Robert W. Platt, PhD; Matthew Dahl, BSc; Colin R. Dormuth, ScD; Kristin K. Clemens, MD, MSc; Madeleine Durand, MD, MSc; Nianping Hu, MD, PhD; David N. Juurlink, MD, PhD; J. Michael Paterson, MSc; Laura E. Targownik, MD, MSHS; Tanvir C. Turin, MD, PhD; Pierre Ernst, MD, MSc; and the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators
Includes: Supplemental Content

Importance  The association between incretin-based drugs, such as dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) agonists, and acute pancreatitis is controversial.

Objective  To determine whether the use of incretin-based drugs, compared with the use of 2 or more other oral antidiabetic drugs, is ...

Original Investigation 
Jean-Luc Faillie, MD, PhD; Oriana H. Yu, MD, MSc; Hui Yin, MSc; Dominique Hillaire-Buys, MD, PhD; Alan Barkun, MD, MSc; Laurent Azoulay, PhD
Includes: Supplemental Content

Importance  The use of dipeptidyl-peptidase–4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues—a group of drugs used in the management of type 2 diabetes mellitus—may be associated with an increased risk of bile duct and gallbladder disease. To date, no observational study has assessed this possible association....

Original Investigation 
Peter Nordström, PhD; Nancy L. Pedersen, PhD; Yngve Gustafson, PhD; Karl Michaëlsson, PhD; Anna Nordström, PhD
Includes: Supplemental Content

Importance  Observational studies have shown that obesity is a major risk factor for cardiovascular disease and death. The extent of genetic confounding in these associations is unclear.

Objective  To compare the risk of myocardial infarction (MI), type 2 diabetes, and death in monozygotic (MZ) twin pairs ...

Original Investigation 
Mingyang Song, MD, ScD; Teresa T. Fung, ScD; Frank B. Hu, MD, PhD; Walter C. Willett, MD, DrPH; Valter D. Longo, PhD; Andrew T. Chan, MD, MPH; Edward L. Giovannucci, MD, ScD
Includes: Supplemental Content

Importance  Defining what represents a macronutritionally balanced diet remains an open question and a high priority in nutrition research. Although the amount of protein may have specific effects, from a broader dietary perspective, the choice of protein sources will inevitably influence other components of diet and may ...

Invited Commentary 
David J. Davidson, MD; Michael H. Davidson, MD

The risk of developing coronary heart disease (CHD) is determined by both lifestyle and genetics. Previous twin studies1 have indicated that heritable factors may account for as much as 30% to 60% of the variation in risk. Monozygotic twins have identical DNA, but by evaluating discordance in ...

Invited Commentary 
Adam J. Schoenfeld, MD; Robert M. Wachter, MD

Transfer of care of patients from one physician to another—referred to as the handoff—is a period laden with vulnerabilities. Miscommunication during handoffs is one of the most common preventable sources of adverse events in the hospital. Since 2003, when resident duty-hour restrictions were implemented in the United ...

Research Letter 
Stephanie K. Mueller, MD, MPH; Catherine Yoon, MS; Jeffrey L. Schnipper, MD, MPH

This cohort study evaluates the effect of a web-based handoff tool on rates of medical errors in adult medical and surgical patients.

Research Letter 
Emily B. Rubin, MD, JD; Anna E. Buehler, BS; Scott D. Halpern, MD, PhD

This cohort study examines how hospitalized patients with serious illnesses evaluate states of cognitive or functional debility relative to death.

Comment & Response  FREE
R. Adams Dudley, MD, MBA

To the Editor The published version of our recent article “Pharmaceutical Industry–Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries”1 referenced an outdated version of the American Medical Association Council on Ethical and Judicial Affairs’ Opinion on Gifts to Physicians From Industry. The current guideline states that ...

Correction  FREE

In the Original Investigation titled “Pharmaceutical Industry–Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries,”1 published online June 20, 2016, there was a reference to an outdated version of the American Medical Association (AMA) Council on Ethical and Judicial Affairs’ Opinion on Gifts to Physicians from Industry, ...

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts